fda update on laboratory developed tests oversight
Download
Skip this Video
Download Presentation
FDA Update on Laboratory Developed Tests Oversight

Loading in 2 Seconds...

play fullscreen
1 / 5

FDA Update on Laboratory Developed Tests Oversight - PowerPoint PPT Presentation


  • 56 Views
  • Uploaded on

FDA Update on Laboratory Developed Tests Oversight. Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division of Human Tissues, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research,

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' FDA Update on Laboratory Developed Tests Oversight' - vance-merrill


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
fda update on laboratory developed tests oversight

FDA Update on Laboratory Developed Tests Oversight

Laura M. St. Martin, M.D., M.P.H.

Acting Branch Chief,

Human Tissues and Reproduction Branch,

Division of Human Tissues,

Office of Cellular, Tissue and Gene Therapies,

Center for Biologics Evaluation and Research,

Food and Drug Administration

ACOT Meeting, February 28, 2012

background
Background
  • ACOT meeting (August 23-24, 2011) agenda item regarding:
    • FDA guidance document on analyte specific reagents (Sept 2007), and draft guidance on research use only/investigational use only in vitro diagnostics (June 2011)
    • Concerns over FDA proposed plan to provide greater oversight for laboratory developed tests (LDTs)
    • Specific concerns re: potential effect on the fields of histocompatibility and immunogenetics
fda involvement in public discussion
FDA Involvement in Public Discussion
  • FDA convened public meeting in July 2010 to gather input on our intention to propose a regulatory framework to address LDTs
  • FDA received over 100 comments to public docket for IUO/RUO draft guidance from stakeholders expressing support and concern
  • FDA has repeatedly stated in public that any framework will be phased in according to risk, and there will be ample opportunity for stakeholders to provide input
stakeholder input encouraged
Stakeholder Input Encouraged
  • FDA will consider concerns raised as we develop policies applicable to analyte specific reagents and laboratory devices indicated for research use only, including concerns related to the needs of small patient populations
  • FDA encourages commentary from stakeholders to inform its development of policy related to these reagents, tests, and devices
fda commitment
FDA Commitment
  • FDA recognizes
    • value of high quality histocompatibility and immunogenetic tests in achieving OPTN goals
    • value and need for availability of tests for high-resolution HLA typing in unrelated donor hematopoietic stem cell transplantation
  • FDA will provide additional opportunity for input and discussion before taking new steps toward regulation of LDTs used in organ and stem cell transplantation
ad